Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
4.010
+0.050 (1.26%)
At close: Nov 13, 2026, 4:00 PM EST
4.010
0.00 (0.00%)
After-hours: Nov 13, 2026, 4:15 PM EST
Artiva Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
134
Market Cap
198.22M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 251.00K | -33.24M | -99.25% |
| Dec 31, 2023 | 33.49M | 28.56M | 579.21% |
| Dec 31, 2022 | 4.93M | 2.93M | 146.30% |
| Dec 31, 2021 | 2.00M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Compugen | 75.93M |
| Alpha Cognition | 15.26M |
| MediWound | 11.86M |
| Pyxis Oncology | 11.04M |
| Fate Therapeutics | 4.75M |
| Entrada Therapeutics | 3.98M |
| Upstream Bio | 2.87M |
| Sol-Gel Technologies | 1.80M |
ARTV News
- 4 days ago - Artiva Biotherapeutics Quarterly report: Q3 2026 - Filings
- 15 days ago - Artiva Biotherapeutics downgraded to Hold from Buy at Jefferies - TheFly
- 15 days ago - Artiva Biotherapeutics downgraded to Hold from Buy at Jefferies - TheFly
- 17 days ago - Why Is Artiva Biotherapeutics Stock (ARTV) Down 31% Today? - TipRanks
- 17 days ago - Artiva Biotherapeutics downgraded to Hold at Needham after discontinuing AlloNK - TheFly
- 17 days ago - Artiva Biotherapeutics downgraded to Hold from Buy at Needham - TheFly
- 17 days ago - Artiva Biotherapeutics downgraded to Neutral at Wedbush after patient death - TheFly
- 17 days ago - Artiva Biotherapeutics downgraded to Neutral from Outperform at Wedbush - TheFly